ArticleProceedings of the National Academy of Sciences of the United States of America1991
Intracellular distribution of microinjected antisense oligonucleotides.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 367 citations in OpenAlex.
- Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1.American journal of human genetics · 2026Article
- Development of a macrophage polarization-modulating therapeutic agent for osteoarthritis treatment.Journal of orthopaedic surgery and research · 2025Review
- Endosomal Escape and Nuclear Localization: Critical Barriers for Therapeutic Nucleic Acids.Molecules (Basel, Switzerland) · 2024Review
- Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.International journal of molecular sciences · 2022Review
- gEL DNA: A Cloning- and Polymerase Chain Reaction-Free Method for CRISPR-Based Multiplexed Genome Editing.The CRISPR journal · 2021Article
- Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs.Pharmaceutics · 2021Review
- Development of a novel DsRed-NLS vector with a monopartite classical nuclear localization signal.3 Biotech · 2019Article
- Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression.Nucleic acids research · 2019Article
- Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro.Nucleic acid therapeutics · 2017Article
- Quantification and real-time tracking of RNA in live cells using Sticky-flares.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Article
- Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.Human gene therapy · 2013Review
- Towards characterization of DNA structure under physiological conditions in vivo at the single-molecule level using single-pair FRET.Nucleic acids research · 2012Article
- LNA-based oligonucleotide electrotransfer for miRNA inhibition.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Deoxyribozymes and bioinformatics: complementary tools to investigate axon regeneration.Cell and tissue research · 2012Review
- RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.Pharmaceutical research · 2011Review
- The role of mesopontine NGF in sleep and wakefulness.Brain research · 2011Article
- Intracellular traffic of oligodeoxynucleotides in and out of the nucleus: effect of exportins and DNA structure.Oligonucleotides · 2010Article
- Polycation-induced cell membrane permeability does not enhance cellular uptake or expression efficiency of delivered DNA.Molecular pharmaceutics · 2010Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisense oligomers constitute an attractive class of specific tools for genetic analysis and for potential therapeutic applications. Targets with different cellular locations have been described, such as mRNA translation initiation sites, pre-mRNA splicing sites, or the genes themselves. However the mechanism(s) of action and the intracellular distribution of antisense oligomers remain poorly understood. Antisense oligomers conjugated with various fluorochromes or with BrdUrd were microinjected into the cytoplasm of somatic cells, and their cellular distribution was monitored by fluorescence microscopy in fixed and nonfixed cells. A fast translocation in the nuclei and a concentration on nuclear structures were observed whatever probe was used. Nuclear transport occurs by diffusion since it is not affected by depletion of the intracellular ATP pool, temperature, or excess unlabeled oligomer. Accumulation of the oligomers in the nuclei essentially takes place on a set of proteins preferentially extracted between 0.2 M and 0.4 M NaCl as revealed by crosslinking of photosensitive oligomers. The relationship between nuclear location of antisense oligomers and their mechanism of action remains to be ascertained and could be of major interest in the design of more efficient antisense molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.